Clinical trials: Dementia Mild
Mild-moderate Alzheimer's Disease
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
The objective of this study is to evaluate the efficacy and safety of DHP1401 in patients with mild-moderate Alzheimer's disease treated with donepezil
- Trial name
- NCT03055741
- Testing
- Donepezil, DHP1401
- Where
- 16 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
Alzheimer Disease, Mild Cognitive Impairment
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants.
- Trial name
- 2-HOBA (NCT06432166)
- Testing
- 2-hydroxybenzylamine acetate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- MTI Biotech Inc
Mild Cognitive Impairment, Mild Dementia
Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia
This pilot study investigates effects of a digital behavioral activation therapy in treating patients with mild cognitive impairment and mild dementia, applying a randomized controlled parallel group design.
- Trial name
- NCT06149013
- Testing
- MindAhead Active, Treatment-as-usual
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- MindAhead UG
Alzheimer's Disease
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00257673
- Testing
- MEM 1003
- Where
- 57 sites in United States
- Volunteers
- 183 people
- Sponsor
- Memory Pharmaceuticals
Mild Cognitive Impairment
A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients
This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this…
- Trial name
- NCT01594541
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Pamlab, Inc.
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
To evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of Rivastigmine patch in the Japanese population.
- Trial name
- NCT01614886
- Testing
- Active Comparator, ENA713
- Where
- 50 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Novartis Pharmaceuticals
Mild to Moderate Alzheimer's Disease
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.
- Trial name
- ETHERAL-US (NCT03867253)
- Testing
- ORY-2001 Low dose, ORY-2001 High dose
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Oryzon Genomics S.A.
Alzheimer's Disease
Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor
This study is designed to evaluate the efficacy on improving cognitive performance as well as the safety, tolerability, and pharmacokinetics (PK) of NBI-1117567 administered once daily (QD) in adults with mild to moderate AD who…
- Trial name
- NCT07832383
- Testing
- NBI-1117567
- Volunteers
- 135 people
- Sponsor
- Neurocrine Biosciences
Alzheimer's Disease
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00809510
- Testing
- ABT-089
- Where
- 22 sites in United States
- Volunteers
- 63 people
- Sponsor
- Abbott
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT01662882
- Testing
- florbetapir (18F)
- Where
- 2 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00359944
- Testing
- AC-3933, Sugar Pill
- Where
- 34 sites in United States
- Volunteers
- 171 people
- Sponsor
- Sumitomo Pharma America, Inc.
Mild Dementia
The Efficacy and Safety of tDCS in Patients With Mild Dementia
This study evaluated the effectiveness and safety of improving Mild Dementia by applying tDCS for 26 weeks to patients with Mild Dementia.
- Trial name
- NCT05495113
- Testing
- YMS-201B (Device: Mind STIM)
- Where
- 2 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Ybrain Inc.
Alzheimer's Disease
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks.
- Trial name
- NCT00838110
- Testing
- Dimebon
- Where
- 118 sites in United States, Canada and 1 more
- Volunteers
- 742 people
- Sponsor
- Pfizer
Early Onset Alzheimer Disease, Mild Cognitive Impairment
Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain
Establishment of a BNA reference database for the Adult and Elderly Population. Hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical…
- Conditions
- Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
- Trial name
- (BNA™) (NCT02875496)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Alzheimer Disease
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
This first-time-in-man study is mainly designed to assess the safety and tolerability of AADvac1 in the treatment of Alzheimer's disease.
- Trial name
- NCT01850238
- Testing
- AADvac1
- Where
- 3 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Axon Neuroscience SE
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Alzheimer's Disease
Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
The purpose of this study is to demonstrate that donepezil slows the progression of Alzheimer's disease (AD) using magnetic resonance imaging (MRI) of the brain to measure the volume of the hippocampus in patients with…
- Trial name
- NCT00403520
- Testing
- Experimental 1
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease
The purpose of this study is to test if the investigational medication, ABT-384, is a safe and effective treatment for adults with mild-to-moderate Alzheimer's Disease.
- Trial name
- NCT01137526
- Testing
- ABT-384, donepezil
- Where
- 30 sites in Russia, South Africa and 2 more
- Volunteers
- 267 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Alzheimer's Disease
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate…
- Trial name
- NOURISH-AD (NCT01741194)
- Testing
- AC-1204
- Where
- 82 sites in United States
- Volunteers
- 418 people
- Sponsor
- Cerecin